Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

被引:165
作者
Bigot, Frederic [1 ]
Castanon, Eduardo [1 ]
Baldini, Capucine [1 ]
Hollebecque, Antoine [1 ]
Calmona, Alberto [2 ]
Postel-Vinay, Sophie [1 ]
Angevin, Eric [1 ]
Armand, Jean-Pierre [1 ]
Ribrag, Vincent [1 ]
Aspeslagh, Sandrine [1 ]
Varga, Andrea [1 ]
Bahleda, Rastislav [1 ]
Menis, Jessica [1 ]
Gazzah, Anas [1 ]
Michot, Jean-Marie [1 ]
Marabelle, Aurelien [1 ]
Soria, Jean-Charles [1 ]
Massard, Christophe [1 ]
机构
[1] Univ Paris Sud, Gustave Roussy Canc Campus, Drug Dev Dept, Villejuif, France
[2] Hosp Univ Morales Meseguer, Hematol & Med Oncol Dept, Calle Marques de los Velez S-N, Murcia, Spain
关键词
Developmental drugs; Phase I studies; Immunotherapy; Prognostic score; NEUTROPHIL-LYMPHOCYTE RATIO; TUMOR-INFILTRATING LYMPHOCYTES; CELL CARCINOMA; CANCER; NIVOLUMAB; SURVIVAL; PEMBROLIZUMAB; DOCETAXEL; THERAPY; CONTEXT;
D O I
10.1016/j.ejca.2017.07.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Life expectancy evaluation is crucial when selecting patients who may benefit from phase I studies. The Royal Marsden Hospital (RMH) prognostic score, based on three objective variables (number of metastatic sites, lactate dehydrogenase (LDH) and serum albumin) was validated in patients treated with cytotoxics and targeted therapies. We aimed to determine if those factors were applicable to immune-checkpoint therapies (ICTs) in phase I trials and to evaluate new variables that may preclude a better prognosis in patients receiving ICT. Patients and methods: We conducted a retrospective analysis of survival risk factors in a discovery cohort of 155 patients enrolled into ICT phase I trials at our institution. We computed univariate analysis and multivariate analysis (MVA) of demographics, clinical and biological data to assess their prognostic value for overall survival (OS). MVA results were used to build a prognostic score for OS. A validation cohort of 113 patients enrolled in phase I ICT trials was used to prospectively validate this score. Results: A total of 155 patients (M/F: 83/72; median age 59) receiving an experimental ICT between March 2012 and January 2016 were included in the discovery cohort. An MVA assessing the RMH score variables showed that low albumin (hazard ratio [HR] 1.73, 95% confidence interval [CI] 1.05-2.86) and LDH > upper limit normal (ULN) (HR 1.88, 95% CI 1.12-3.15) were independent negative prognostic factors for OS. Interestingly, neutrophil-to-lymphocyte ratio (NLR) > 6 (HR 1.75, 95% CI 1.04-2.95) was associated with a decrease in OS. The number of metastases was not associated with a poorer outcome for this ICT cohort (HR 0.83, 95% CI 0.51-1.35). A risk score based on the results of the MVA (NLR > 6 = 1; LDH > ULN = 1; albumin < 35 g/l = 1) showed that patients presenting a high score (> 1) had a significantly shorter OS (20.4 weeks; 95% CI 5.7-35.2) compared to those with a low score (0 or 1) (68.9 weeks; 95% CI 50-83.7) (HR 2.9, 95% CI 1.87-4.64). In the validation cohort of 113 patients, again the patients presenting a high score showed an inferior OS (HR 6.3, 95% CI 2.7-14.8). Conclusion: In ICT phase I trials, traditional prognostic variables included in the RMH score may be suboptimal to determine patient's prognosis. In this context, the NLR is a significant prognostic variable. The Gustave Roussy Immune Score, based on albumin, LDH and NLR, allows a better selection of patients for ICT phase I trials. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:212 / 218
页数:7
相关论文
共 42 条
[1]  
Aneja P, 2014, JNCI-J NATL CANCER I, V106
[2]   Immunostimulatory monoclonal antibodies in cancer therapy [J].
Aranda, Fernando ;
Vacchelli, Erika ;
Eggermont, Alexander ;
Galon, Jerome ;
Fridman, Wolf Herve ;
Zitvogel, Laurence ;
Kroemer, Guido ;
Galluzzi, Lorenzo .
ONCOIMMUNOLOGY, 2014, 3 (02)
[3]   Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience [J].
Arkenau, H-T ;
Olmos, D. ;
Ang, J. E. ;
de Bono, J. ;
Judson, I. ;
Kaye, S. .
BRITISH JOURNAL OF CANCER, 2008, 98 (06) :1029-1033
[4]   90-Days mortality rate in patients treated within the context of a phase-I trial: How should we identify patients who should not go on trial? [J].
Arkenau, Hendrik-Tobias ;
Olmos, David ;
Ang, Joo Ern ;
Barriuso, Jorge ;
Karauasilis, Vasilios ;
Ashley, Sue ;
de Bono, Johann ;
Judson, Ian ;
Kaye, Stan .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (11) :1536-1540
[5]   Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials [J].
Arkenau, Hendrik-Tobias ;
Barriuso, Jorge ;
Olmos, David ;
Ang, Joo Ern ;
de Bono, Johann ;
Judson, Ian ;
Kaye, Stan .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2692-2696
[6]   Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials [J].
Bachelot, T ;
Ray-Coquard, I ;
Catimel, G ;
Ardiet, C ;
Guastalla, JP ;
Dumortier, A ;
Chauvin, F ;
Droz, JP ;
Philip, T ;
Clavel, M .
ANNALS OF ONCOLOGY, 2000, 11 (02) :151-156
[7]   Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma [J].
Bellmunt, J. ;
de Wit, R. ;
Vaughn, D. J. ;
Fradet, Y. ;
Lee, J. -L. ;
Fong, L. ;
Vogelzang, N. J. ;
Climent, M. A. ;
Petrylak, D. P. ;
Choueiri, T. K. ;
Necchi, A. ;
Gerritsen, W. ;
Gurney, H. ;
Quinn, D. I. ;
Culine, S. ;
Sternberg, C. N. ;
Mai, Y. ;
Poehlein, C. H. ;
Perini, R. F. ;
Bajorin, D. F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) :1015-1026
[8]  
Biffl WL, 1999, ARCH SURG-CHICAGO, V134, P1331
[9]   Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].
Brahmer, Julie ;
Reckamp, Karen L. ;
Baas, Paul ;
Crino, Lucio ;
Eberhardt, Wilfried E. E. ;
Poddubskaya, Elena ;
Antonia, Scott ;
Pluzanski, Adam ;
Vokes, Everett E. ;
Holgado, Esther ;
Waterhouse, David ;
Ready, Neal ;
Gainor, Justin ;
Aren Frontera, Osvaldo ;
Havel, Libor ;
Steins, Martin ;
Garassino, Marina C. ;
Aerts, Joachim G. ;
Domine, Manuel ;
Paz-Ares, Luis ;
Reck, Martin ;
Baudelet, Christine ;
Harbison, Christopher T. ;
Lestini, Brian ;
Spigel, David R. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135
[10]   Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection? [J].
Chau, Nicole G. ;
Florescu, Ana ;
Chan, Kelvin K. ;
Wang, Lisa ;
Chen, Eric X. ;
Bedard, Philippe ;
Oza, Amit M. ;
Siu, Lillian L. .
BMC CANCER, 2011, 11